Intravenous dolasetron mesilate ameliorates postoperative nausea and vomiting

Canadian Journal of Anaesthesia

Volumn 44, Issue 2, 1997, Pages 173-181

  Diemunsch, P ^a   Leeser, J ^b   Feiss, P ^c   D'Hollander, A ^d   Bradburn, B G ^e   Paxton, D ^f   Whitmore, J ^g   Panouillot, P ^g   Nave S ^h   Brown, R A ^g   Hahne, W F ^g  

^a UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^b ONZE LIEVE VROUWE GASTHUIS   (Netherlands)

^c Hopital Erasme ^*

^d ERASME HOSPITAL   (Belgium)

^e KENT AND CANTERBURY HOSPITAL   (United Kingdom)

^f ROYAL VICTORIA HOSPITAL   (United Kingdom)

^g SANOFI   (France)

^h Roche   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DOLASETRON MESILATE; PLACEBO;

ADULT; ARTICLE; CARDIOTOXICITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEADACHE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VOMITING;

EID: 0030914552     PISSN: 0832610X     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03013007     Document Type: Article

References (33)

1. Camu F, Lauwers MH, Verbessem D. Incidence and aetiology of postoperative nausea and vomiting. Eur J Anaesth 1992; 9(Suppl 6): 25-31.
2. Watcha MF, White PF. Postoperative nausea and vomiting. Its etiology, treatment, and prevention. Anesthesiology 1992; 77: 162-84.
3. Hirsch J. Impact of postoperative nausea and vomiting in the surgical setting. Anaesthesia 1994; 49(Suppl): 30-3.
4. Kenny GNC. Risk factors for postoperative nausea and vomiting. Anaesthesia 1994; 49(Suppl): 6-10.
5. Green G, Jonsson L. Nausea: the most important factor determining length of stay after ambulatory anaesthesia. A comparative study of isoflurane and/or propofol techniques. Acta Anaesthesiol Scand 1993; 37: 742-6.
6. 3 antagonists in postoperative nausea and vomiting. Br J Anaesth 1992; 69: 63S-8.
7. 3 receptor antagonist. Drug Dev Res 1995; 34: 289-96.
8. 3 antagonists MDL 73147EF (dolasetron mesilate) and MDL 74156 in NG108-15 neuroblastoma x glioma cells. Eur J Pharmacol 1992; 219: 9-13.
9. Dixon RM, Cramer M, Shah AK, Whitmore J, Benedict CR, Hahne WF. Single-dose, placebo-controlled, phase I study of oral dolasetron. Pharmacotherapy 1996; 16: 245-52.
10. Hunt TL, Cramer M, Shah A, Stewart W, Benedict CR, Hahne WF. A double-blind, placebo-controlled, dose-ranging safety evaluation of single-dose intravenous dolasetron in healthy male volunteers. J Clin Pharmacol 1995; 35: 705-12.
11. Hunt TL, Cramer M, Christy-Bittel J, et al. Multiple-dose, placebo-controlled, phase I study of oral dolasetron. Pharmacotherapy 1996; 16: 253-60.
12. Chevallier B, Cappalaere P, Splinter T, et al. Double-blind, multicentre comparison of intravenous dolasetron mesilate and metoclopramide in the prevention of nausea and vomiting in cancer patients receiving high-dose cisplatin chemotherapy. Support Care Cancer 1997; in press.
13. Harman GS, Omura GA, Ryan K, Hainsworth JD, Cramer MB, Hahne WF. A randomized, double-blind comparison of single-dose and divided multiple-dose dolasetron for cisplatin-induced emesis. Cancer Chemother Pharmacol 1996; 38: 323-8.
14. Hesketh PJ, Gandara DR, Hesketh AM, et al. Dose-ranging evaluation of the antiemetic efficacy of intravenous dolasetron in patients receiving chemotherapy with doxorubicin or cyclophosphamide. Support Care Cancer 1996; 4: 141-6.
15. Kasimis B, Tapazoglou E, Schulman P, et al. A double-blind, randomized study of two different dose regimens of intravenous dolasetron in patients receiving high-dose cisplatin chemotherapy. Cancer Invest 1997; in press.
16. Yeilding A, Bertoli L, Eisenberg P, et al. Antiemetic efficacy of two different single intravenous doses of dolasetron in patients receiving high-dose cisplatin-containing chemotherapy. Am J Clin Oncol 1997; in press.
17. Melson T, Graczyk SG, Hickok C, McKenzie R, Kallar S. Prevention of nausea and vomiting with dolasetron after outpatient laparoscopic gynecologic surgery. Anesthesiology 1995; 83: A7.
18. Kovac A, Melson T, Graczyk S, Scuderi P, Watkins WD. Treatment of postoperative nausea and vomiting with single doses of IV dolasetron: a multicenter trial. Anesthesiology 1995; 83: A6.
19. Bodner M, White PF. Antiemetic efficacy of ondansetron after outpatient laparoscopy. Anesth Analg 1991; 73: 250-4.
20. Dupeyron JP, Conseiller C, Levarlet M, et al. The effect of oral ondansetron in the prevention of postoperative nausea and vomiting after major gynaecological surgery performed under general anaesthesia. Anaesthesia 1993; 48: 214-8.
21. Kovac A, McKenzie R, O'Connor T, et al. Prophylactic intravenous ondansetron in female outpatients undergoing gynaecological surgery: a multicentre dose-comparison study. Eur J Anaesth 1992; 9(Suppl 6): 37-47.
22. Larijani GE, Gratz I, Afshar M, Minassian S. Treatment of postoperative nausea and vomiting with ondansetron: a randomised, double-blind comparison with placebo. Anesth Analg 1991; 73: 246-9.
23. McKenzie R, Kovac A, O'Connor T, et al. Comparison of ondansetron versus placebo to prevent postoperative nausea and vomiting in women undergoing ambulatory gynecologic surgery. Anesthesiology 1993; 78: 21-8.
24. Rust M, Cohen LA. Single oral dose ondansetron in the prevention of postoperative nausea and emesis. Anaesthesia 1994; 49(Suppl): 16-23.
25. 3 antagonist ondansetron. Anesthesiology 1993; 78: 15-20.
26. Markham A, Sorkin EM. Ondansetron. An update of its therapeutic use in chemotherapy-induced and postoperative nausea and vomiting. Drugs 1993; 45: 931-52.
27. Milne RJ, Heel RC. Ondansetron. Therapeutic use as an antiemetic. Drugs 1991; 41: 574-95.
28. Plosker GL, Goa KL. Granisetron. A review of its pharmacological properties and therapeutic use as an antiemetic. Drugs 1991; 42: 805-24.
29. Lee CR, Plosker GL, McTavish D. Tropisetron. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential as an antiemetic. Drugs 1993; 46: 925-43.
30. Bryson JC. Clinical safety of ondansetron. Semin Oncol 1992; 19(Suppl 15): 26-32.
31. Finn AL. Toxicity and side effects of ondansetron. Semin Oncol 1992; 19 (Suppl 10): 53-60.
32. Wetchler BV. Postoperative nausea and vomiting in day-case surgery. Br J Anaesth 1992; 69: 33S-9.
33. White PF, Watcha MF. Are new drugs cost-effective for patients undergoing ambulatory surgery? Anesthesiology 1993; 78: 2-5.